drugset / Trial / NCT05374343
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Rongliflozin in Type 2 Diabetic Subjects With Renal Impairment
Non-randomizedParallel-groupOpen-labelTreatment
Summary
To evaluate the pharmacokinetic characteristics of pyroglutamate rongliflozin capsules in type 2 diabetic subjects with normal renal function and mild to moderate renal impairment.
Timeline
- Start
- 2022-05-05
- Primary completion
- 2023-08-24
- Completion
- 2023-08-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rongliflozin | Small molecule | 50 mg | Oral |